Citation Impact
Citing Papers
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
2008
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer
2012
ESUR prostate MR guidelines 2012
2012 Standout
Characteristics of the Clinical Findings in Patients with Idiopathic Thrombocytopenic Purpura Who are Positive for Anti-phospholipid Antibodies.
1997
Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis
2020
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature
2015
Regulation of the Expression of the Prostate-specific Antigen by Claudin-7
2003
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
2006 Standout
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
2006 Standout
Long‐term follow‐up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis
2003
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Value of Targeted Prostate Biopsy Using Magnetic Resonance–Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-specific Antigen
2013
Intensive physical training in geriatric patients after severe falls and hip surgery
2002
Management of patients with chronic, refractory idiopathic thrombocytopenic purpura
2000
Secondary immune thrombocytopenic purpura
2007
Hereditary dilated cardiomyopathy
1995
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
The Risk–Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava
2002 Standout
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
Antiphospholipid antibodies in adults with immune thrombocytopenic purpura
2008
Phytoestrogens: a review of the present state of research
2003
Idiopathic thrombocytopenic purpura in elderly patients: A study of 47 cases from a single reference center
2008
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Molecular determinants of resistance to antiandrogen therapy
2003 Standout
Coordinated regulation of myeloid cells by tumours
2012 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer
2009
Phytotherapy in the treatment of benign prostatic hyperplasia: an update
1999
Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review
2009
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
2003 Standout
Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population‐based cohort of 245 patients
2003
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Initial Treatment of Immune Thrombocytopenic Purpura with High-Dose Dexamethasone
2003
Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor
2007
Overview of 321 patients with idiopathic thrombocytopenic purpura
2002
The Bleeding Risk and Natural History of Idiopathic Thrombocytopenic Purpura in Patients With Persistent Low Platelet Counts
2000
Clinical and genetic issues in familial dilated cardiomyopathy
2005
von Hippel-Lindau disease
2003 Standout
Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies
2015
Proximal femur fracture in older patients - rehabilitation and clinical outcome
2003
OVERWHELMING POSTSPLENECTOMY INFECTION
1996
Immune Thrombocytopenic Purpura
2002 Standout
The Antiphospholipid Syndrome
2002 Standout
A Review of 12 Commonly Used Medicinal Herbs
1998
High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults
2004
Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature
2007
Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate
2013
Sickle-cell disease
2010 Standout
The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey
2008 StandoutNobel
Promise and pitfalls of quantitative imaging in oncology clinical trials
2012
Management of Immune Thrombocytopenic Purpura in Adults
2004
Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission
2005
Myocarditis
2000 Standout
Hypertrophic Cardiomyopathy
2002 Standout
A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging–Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial
2013
Serenoa repensfor benign prostatic hyperplasia
2009
Retrospective Analysis of Patients with Idiopathic Thrombocytopenic Purpura from Eastern Anatolia
2007
Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?
2006
Wnt/β-Catenin activation promotes prostate tumor progression in a mouse model
2010
Controlling Cell Behavior Electrically: Current Views and Future Potential
2005 Standout
Evaluating the components of the Exercise Plus Program: rationale, theory and implementation
2002
Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management
2007
Immune thrombocytopenic purpura in adults
2007
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study
2008
Current management of adult idiopathic thrombocytopenic purpura in practice: a cohort study of 201 patients from a single center1
2004
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry
1996
Evidence from family studies for autoimmunity in dilated cardiomyopathy
1994
Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients
2006
Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma.Identification of a subset at high risk of treatment failure
1994
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
2007
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
Multiparametric Magnetic Resonance Imaging Guided Diagnostic Biopsy Detects Significant Prostate Cancer and could Reduce Unnecessary Biopsies and Over Detection: A Prospective Study
2014
Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study
2001
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?
2002
α 1 -Adrenergic Receptors and Their Inhibitors in Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
2004
Current Options for the Treatment of Idiopathic Thrombocytopenic Purpura
2007
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]
1996 Standout
Standardization of Multiparametric Prostate MR Imaging Using PI-RADS
2014
Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: Profile comparison
2013
Bladder Cancer
2020 Standout
RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY
1999
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Complementary/Alternative Medicine Use in a Comprehensive Cancer Center and the Implications for Oncology
2000 Standout
Contemporary Definitions and Classification of the Cardiomyopathies
2006 Standout
Activation and Differentiation of Autoreactive B-1 Cells by Interleukin 10 Induce Autoimmune Hemolytic Anemia in Fas-deficient Antierythrocyte Immunoglobulin Transgenic Mice
2002 StandoutNobel
How I treat idiopathic thrombocytopenic purpura (ITP)
2005
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Molecular Basis of Familial Cardiomyopathies
1995
Accuracy of Multiparametric MRI for Prostate Cancer Detection: A Meta-Analysis
2014
The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy.
2006
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies
1996 Standout
Long-term outcomes in adults with chronic ITP after splenectomy failure
2004
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
2004
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
Claudins and the Modulation of Tight Junction Permeability
2013 Standout
Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease
2004
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
2001
The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation
2013
Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer
2015
Molecular Mechanisms of Myocardial Remodeling
1999 Standout
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
2001 StandoutScienceNobel
Interventions for preventing falls in older people living in the community
2012 Standout
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten
2004 StandoutNobel
Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer
2015 Standout
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
2001
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
2008 Standout
Works of Alessandro Sciarra being referenced
Plant extracts in BPH.
1993
Magnetic Resonance Spectroscopic Imaging (1H-MRSI) and Dynamic Contrast-Enhanced Magnetic Resonance (DCE-MRI): Pattern Changes From Inflammation to Prostate Cancer
2010
Advances in Magnetic Resonance Imaging: How They Are Changing the Management of Prostate Cancer
2011
Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR)
2011
Distribution of Inflammation, Pre-Malignant Lesions, Incidental Carcinoma in Histologically Confirmed Benign Prostatic Hyperplasia: A Retrospective Analysis
2003
Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer
2009
Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?
2003
Inflammation and Chronic Prostatic Diseases: Evidence for a Link?
2007
Evidence that Serenoa repens Extract Displays an Antiestrogenic Activity in Prostatic Tissue of Benign Prostatic Hypertrophy Patients
1992
Role of magnetic resonance spectroscopic imaging ([1H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA)
2010
Prostate Cancer Gene 3 and Multiparametric Magnetic Resonance Can Reduce Unnecessary Biopsies: Decision Curve Analysis to Evaluate Predictive Models
2013
The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation
2011
Independent value of tumor size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma
2000
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP)
2011
Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer
2008
Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura
1995
DIMA Ploidy, Gleason Score,Pathological Stage and Serum PSALevels as Predictors of Disease-FreeSurvival in C-D(1) Prostatic CancerPatients Submitted to RadicalRetropubic Prostatectomy
1996
Relationship among age, prostate-specific antigen, and prostate volume in men with lower urinary tract symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases
1998
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
2019
Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy
2010
Antiphospholipid Antibodies: Prevalence, Clinical Significance and Correlation to Cytokine Levels in Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma
1993
Surgical Enucleation for Renal Cell Carcinoma (RCC): Prognostic Significance of Tumour Stage, Grade and DNA Ploidy
1997
261 Is prostate biopsy still necessary?
2012
PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations.
2011
602: Characterization of Circulating Blood Dendritic Cell Subsets DC123+ (Lymphoid) and DC11C+ (Myeloid) in Prostate Adenocarcinoma Patients
2007
Familial aggregation of idiopathic dilated cardiomyopathy: clinical features and pedigree analysis in 14 families.
1993
Characterization of circulating blood dendritic cell subsets DC123+ (Lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients
2006
Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura
1994
Very old people can have favorable outcome after hip fracture: 58 patients referred to rehabilitation
2000
459 DETERMINATION OF THE TIME FOR MAXIMAL RESPONSE TO NEOADJUVANT HORMONE THERAPY (LEUPROLIDE) FOR PROSTATE CANCER USING MAGNETIC RESONANCE WITH SPECTROSCOPY (MRSI) AND DYNAMIC CONTRAST ENHANCEMENT (DCEMR)
2010